Weber Shandwick Healthcare and dna medical communications appointed by UCB to support new brand

Weber Shandwick Healthcare and sister agency dna medical communications have been appointed by UCB to support the epilepsy indication for their new brand, Lacosamide, and will work on an integrated public relations and medical education programme to support the UK launch.

With a strong programme of activities planned, Weber Shandwick is very proud to be working with UCB to tackle the ongoing challenges facing the management and treatment of epilepsy in the UK.